Drug Discovery
By
Is Eli Lilly’s $1.3B Acquisition of Verve the Turning Point for CRISPR-Based Cardiovascular Therapies?
Key Highlights Strategic Bet on Early-Stage InnovationEli Lilly’s acquisition of Verve Therapeutics for up to $1.3 billion marks…
Is HEALWELL AI’s Acquisition of BioPharma Canada’s Biggest AI-Driven CRO Leap Yet—and a Blueprint for Future Clinical Trials?
Key Highlights HEALWELL Targets AI-Driven Scale in CRO with $14.4M BioPharma AcquisitionHEALWELL AI Inc. (TSX: AIDX, OTCQX: HWAIF)…
How Merck’s $3B MoonLake Acquisition the AI-Powered Bet That Will Reignite Late-Phase Biotech and Immune-Driven Precision Trials?
Key Highlights Merck Moves Decisively: A $3 Billion Signal to the Late-Stage Biotech MarketMerck has reportedly offered over…
Can HekaBio and Alfresa’s AI-Driven Alliance Redefine Japan’s Biopharma Access and Launch Asia’s Next AI Commercialization Engine?
Smart Partnerships: HekaBio Leverages Alfresa’s Scale to Localize Global InnovationJapan’s historically delayed access to global therapies may soon…
Is Merck’s $10B Acquisition of Verona a Strategic Masterstroke to Offset Keytruda’s Patent Cliff and Dominate the $30B+ Respiratory Market?
Key Highlights Merck Secures Verona to Bridge Its Post-Keytruda Future Merck & Co. has taken a bold step…
Can Google DeepMind’s Isomorphic Labs Revolutionize Clinical Trials with AI-Designed Drugs Backed by $600M and AlphaFold Breakthrough?
Key Takeaways AI to Clinic: Isomorphic Labs Moves Beyond Design to Human TrialsIsomorphic Labs, the AI drug discovery…
